TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01675557

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: a single oral dose of vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: a single oral dose of vitamin D2

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single oral dose of placebo
Study: NCT02541526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
Study: NCT00957814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: Systematic nutritional orientation program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: Systematic nutritional orientation program
Study: NCT02300090

Intervention type: DEVICE
Intervention: Test Group
Description: Patients receive a mobile phone with the Me \& My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.

Intervention type: OTHER
Intervention: Control Group
Description: Patients in the control group receive only standard care; there are no interventions within this group of patients
Study: NCT03205553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SoC Staged Silo Closure
Description: Serial reductions will be performed with silastic silo placement for staged reduction using umbilical tape ties. The silo is assessed daily on morning rounds by the surgical team. Once the abdominal contents are at the level of the fascia, the abdomen is closed in the operating room. The average day to closure historically from CHND data is 5 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SoC Staged Silo Closure
Description: Serial reductions will be performed with silastic silo placement for staged reduction using umbilical tape ties. The silo is assessed daily on morning rounds by the surgical team. Once the abdominal contents are at the level of the fascia, the abdomen is closed in the operating room. The average day to closure historically from CHND data is 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis Solution/Dextrose 1.5%
Description: Serial reductions will be performed with silastic silo placement for staged reduction with adjuvant direct peritoneal resuscitation (DPR). A JP drain will be securely placed through the top of the silo beneath the fascia at the base of the small bowel mesentery for instillation of dialysate fluid and aspiration of peritoneal fluid. The sterile syringe will then be connected to the JP drain. The dialysate fluid administered via JP drain as a bolus infusion every 6 hours until the abdominal wall is closed (generally 3-5 days), but not to exceed 7 days maximum. Fluid will be warmed at bedside using dry heat not to exceed 37°C/98°F. The initial bolus infusion will be 10 mL/kg of dialysate. If tolerated, each subsequent infusion will be increased by 10 mL/kg up to a goal infusion of 40 mL/kg (to a maximum volume of 100 mL) as tolerated. Dialysate will dwell for 1 hour after instillation of fluid. Any excess fluid will then be removed via JP drain.
Study: NCT04423237

Intervention type: DRUG
Intervention: Deferasirox
Description: DEFERASIROX administered as per clinical practice and according to technical note

Intervention type: DRUG
Intervention: Deferasirox
Description: DEFERASIROX administered as per clinical practice and according to technical note
Study: NCT02848326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Atogepant
Description: Placebo-matching atogepant capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Atogepant
Description: Placebo-matching atogepant capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Atogepant
Description: Placebo-matching atogepant capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching Atogepant
Description: Placebo-matching atogepant capsule.
Study: NCT01313416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-011
Description: 3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m\^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
Study: NCT00637390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
Study: NCT03677648

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos
Study: NCT02999178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00192608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir 500 formulation
Description: NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cross-over arm
Description: either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
Study: NCT03150602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
Study: NCT00762086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AngioPress Intermittent pneumatic compression (IPC) Device
Description: Treatment with Intermittent pneumatic compression (IPC) for PAD

Intervention type: OTHER
Group type: OTHER
Intervention: Medications and Standard walking exercises
Description: Aspirin/Clopidegrol and Standard walking exercises
Study: NCT04123210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03940001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Other Name: (IBI308)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin/paclitaxel
Description: carboplatin AUC 2/paclitaxel 50 mg/m2 weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: IMRT or VMAT
Study: NCT03597490

Intervention type: COMBINATION_PRODUCT
Intervention: Multimodal physical therapy with exercise
Description: Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
Study: NCT04028453

Intervention type: OTHER
Intervention: Survey
Description: There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation survey.
Study: NCT05901948

Intervention type: OTHER
Intervention: Classification
Description: Novel Asherman Scoring Classification
Study: NCT03500861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dry Needling
Description: The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
Study: NCT00301756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01642511

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc-labeled Sulfur Colloid
Description: Control Group: Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5\~1.0 mCi/0.5mL) in the tumor quadrant. Study Group: Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Sentinel Lymph Node Biopsy
Description: Sentinel lymph node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Sentinel Lymph Node Biopsy
Description: Sentinel lymph node biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylthioninium
Description: Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylthioninium
Description: Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphoscintigraphy
Description: Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Description: Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Lymph Node Dissection
Description: ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Mammary Sentinel Lymph Node Biopsy
Description: Internal mammary sentinel lymph node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Mammary Sentinel Lymph Node Biopsy
Description: Internal mammary sentinel lymph node biopsy
Study: NCT02969837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be given on days 1-21 for all cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be given on days 1-21 for all cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22
Study: NCT00059852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT02499666

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
Study: NCT04110288

Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel to treat peripheral arterial disease

Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel to treat peripheral arterial disease

Intervention type: DEVICE
Intervention: Non-drug coated Device Treatment

Intervention type: DEVICE
Intervention: Non-drug coated Device Treatment
Study: NCT02838394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Acupuncture filiform needles are inserted into myofascial trigger points

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham dry needling
Description: Blunted needles will be pressed against the skin, but no actual penetration will occur
Study: NCT02499666

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).

Intervention type: DEVICE
Intervention: Coronary stent
Description: As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty

Intervention type: DEVICE
Intervention: Coronary stent
Description: As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty

Intervention type: DRUG
Intervention: Clopidogrel
Description: As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.

Intervention type: DRUG
Intervention: Clopidogrel
Description: As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
Study: NCT00925626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-Vastus arthrotomy
Description: Sub-vastus arthrotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid - Vastus arthrotomy
Description: Mid-vastus arthrotomy
Study: NCT03542422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.
Study: NCT04249973

Intervention type: OTHER
Intervention: Collection of urine and feces
Description: Urine and feces are collected at the families home. A short questionnaire is filled in by the parents

Intervention type: OTHER
Intervention: Collection of urine and feces
Description: Urine and feces are collected at the families home. A short questionnaire is filled in by the parents

Intervention type: OTHER
Intervention: Collection of urine and feces
Description: Urine and feces are collected at the families home. A short questionnaire is filled in by the parents

Intervention type: OTHER
Intervention: Collection of urine and feces
Description: Urine and feces are collected at the families home. A short questionnaire is filled in by the parents
Study: NCT03145870

Intervention type: OTHER
Group type: OTHER
Intervention: Echoing of the lower limbs and measuring the systolic pressure index
Description: Echoing of the lower limbs and measuring the systolic pressure index
Study: NCT03320577

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Class instruction of breathing exercises
Description: Pranayama Breathing exercises practiced at least 5 times a week and log practice times

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DVD instruction of breathing exercises
Description: Pranayama Breathing exercises practiced at least 5 times a week and log practice times
Study: NCT01828996

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Shock wave therapy
Description: A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
Study: NCT03320577

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Log dinner times
Study: NCT04396561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral group (group P):
Description: In both groups, one reading of mean arterial pressure and heart rate were taken before induction of general anaesthesia and were defined as baseline readings and then were recorded intra-operatively at 15 min intervals.~Additional bolus doses of fentanyl 0.5µg/kg were given when the mean arterial blood pressure or heart rate raised above 20% of baseline levels.
Study: NCT01828996

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave therapy
Description: A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
Study: NCT02923947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib; AZD9291
Description: 80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib; AZD9291
Description: 80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
Study: NCT01064349

Intervention type: DRUG
Intervention: Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
Description: Trastuzumab or Lapatinib
Study: NCT02200965

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: My Diabetes, My Information, My Plan Document
Description: A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: My Diabetes, My Information, My Plan Document
Description: A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.